Extraction of tamoxifen and its metabolites from formalin-fixed, paraffin-embedded tissues: An innovative quantitation method using liquid chromatography and tandem mass spectrometry

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 3, 2014, Pages 475-484

  Ng, Ella S M ^a   Kangarloo, S Bill ^a   Konno, Mie ^a   Paterson, Alexander ^b   Magliocco, Anthony M ^b,c  

^a TOM BAKER CANCER CENTRE   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Breast cancer recurrence; Formalin fixed paraffin embedded tissue; Retrospective analysis; Tamoxifen therapy; Tandem mass spectrometry

Indexed keywords

AFIMOXIFENE; ENDOXIFEN; FORMALDEHYDE; NORTAMOXIFEN; PARAFFIN; TAMOXIFEN; XYLENE;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ISOLATION; DRUG METABOLISM; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY;

BREAST NEOPLASMS; CHROMATOGRAPHY, LIQUID; FEMALE; FORMALDEHYDE; HUMANS; NEOPLASM RECURRENCE, LOCAL; PARAFFIN; PILOT PROJECTS; RETROSPECTIVE STUDIES; TAMOXIFEN; TANDEM MASS SPECTROMETRY;

EID: 84896037098     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2346-z     Document Type: Article

References (34)

1. van Leeuwen FE, Benraadt J, Goebergh JW, Kiemeney LA, Gimbrere CH, Otter R et al (1994) Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343:448-452 (Pubitemid 24059587)
2. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N (1995) Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies: Stockholm Breast Cancer Study Group. J Natl Cancer Inst 87:645-651
3. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388 (Pubitemid 28439961)
4. Cuzick J, Forbes J, Edwards R (2002) First results from the International Breast Cancer Intervention Study: a randomized prevention trial. Lancet 360:817-824 (Pubitemid 35257944)
5. Osborne CK, Coronado E, Allred DC, Wiebe V, DeGregorio M (1991) Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst 83:1477-1482
6. Wolf DM, Langan-Fahey SM, Parker CJ, McCague R, Jordan VC (1993) Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites. J Natl Cancer Inst 85:806-812 (Pubitemid 23150312)
7. MacCallum J, Cummings J, Dixon JM, Miller WR (2000) Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours. Br J Cancer 82:1629-1635 (Pubitemid 30229571)
8. Crewe HK, Ellis SW, Lennard MS, Tucker GT (1997) Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 52:171-178 (Pubitemid 27013472)
9. Desta Z, Ward BA, Soukhova NV, Flockhard DA (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310:1062-1075 (Pubitemid 39108928)
10. Lim YC, Desta Z, Flockhart DA, Skaar TC (2005) Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 55:471-478 (Pubitemid 40568978)
11. Katzenellenbogen BS, Norman MJ, Eckert RL, Peltz SW, Mangel WF (1984) Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxytamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res 44:112-119 (Pubitemid 14178070)
12. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P et al (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758-1764 (Pubitemid 38008898)
13. Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV et al (2004) Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85:151-159 (Pubitemid 38987269)
14. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A et al (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80:61-74 (Pubitemid 43946844)
15. Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R et al (2012) CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 104:441-451
16. Goetz MP, Suman VJ, Hoskin TL, Gnant M, Fillipits M, Safgren SL et al (2013) CYP2D6 metabolism and patient outcome in the Austrian breast and colorectal cancer study group trial (ABCSG) 8. Clin Cancer Res 19(2):500-507
17. Kisanga ER, Gjerde J, Guerrieri-Gonzaga A, Pigatto F, Pesci-Feltri A, Robertson C et al (2004) Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin Cancer Res 10:2336-2343 (Pubitemid 38445691)
18. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW et al (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23(36):9312-9318
19. Gjerde J, Hauglid M, Breilid H, Lundgren S, Varhaug JE, Kisanga ER et al (2008) Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol 19(1):56-61
20. Borges S, Desta Z, Jin Y, Faouzi A, Robarge JD, Philips S et al (2010) Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol 50(4):450-458
21. Antunes M, Linden R, Santos TV, Wallemacq P, Haufroid V, Classen J-F et al (2012) Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy. Ther Drug Monit 34(4):422-431
22. Williams ML, Lennard MS, Martin IJ, Tucker GT (1994) Interindividual variation in the isomerization of 4-hydroxytamoxifen by human liver microsomes: involvement of cytochromes P450. Carcinogenesis 15(12):2733-2738
23. Zheng Y, Sun D, Sharma AK, Chen G, Amin S, Lazarus P (2007) Elimination of antiestrogenic effects of active tamoxifen metabolites by glucuronidation. Drug Metab Dispos 35:1942-1948 (Pubitemid 47481590)
24. Teunissen SF, Rosing H, Koornstra RHT, Linn SC, Schellens JHM, Schinkel AH et al (2009) Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B 877:2519-2529
25. Murdter TE, Schroth W, Bacchus-Gerybadze B, Winter S, Heinkele G, Simon W et al (2011) Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 89(5):708-717
26. Belief V, Boissiere F, Bibeau F, Desmetz C, Berthe ML, Rochaiz P et al (2008) Proteomic analysis of RCL2 paraffin-embedded tissues. J Cell Mol Med 12:2027-2036
27. Nirmalan NJ, Harnden P, Selby PJ, Banks RE (2009) Development and validation of a novel protein extraction methodology for quantitation of protein expression in formalin-fixed paraffin-embedded tissues using western blotting. J Pathol 217:497-506
28. Shi SR, Liu C, Balgley BM, Lee C, Taylor CR (2006) Protein extraction from formalin-fixed, paraffin-embedded tissue sections: quality evaluation by mass spectrometry. J Histochem Cytochem 54:739-743 (Pubitemid 43736896)
29. Bagnato C, Thumar J, Mayya V, Hwang S, Zebroski H, Claffey KP et al (2007) Proteomic analysis of human coronary atherosclerotic plaque: a feasibility study of direct tissue proteomics by liquid-chromatography and tandem mass spectrometry. Mol Cell Proteomics 6:1088-1102 (Pubitemid 47019409)
30. Guo T, Wang W, Rudnick PA, Song T, Li J, Zhuang Z et al (2007) Proteome analysis of microdissected formalin-fixed and paraffin-embedded tissue specimens. J Histochem Cytochem 55:763-772 (Pubitemid 46981773)
31. Scicchitano MS, Dalmas DA, Boyce RW, Thomas HC, Frazier KS (2009) Protein extraction of formalin-fixed, paraffin-embedded tissue enables robust proteomic profiles by mass spectrometry. J Histochem Cytochem 57:849-860
32. Crockett DK, Lin Z, Vaughn CP, Lim MS, Elenitoba-Johnson KSJ (2005) Identification of proteins from formalin-fixed paraffin-embedded cells by LC-MS/MS. Lab Invest 85:1405-1415 (Pubitemid 41509388)
33. Palmer-Toy DE, Krastins B, Sarracino DA, Nadol JB, Merchant SN (2005) Efficient method for the proteomic analysis of fixed and embedded tissues. J Proteome Res 4:2404-2411 (Pubitemid 41814314)
34. Furlanut M, Franceschi L, Pasqual E, Bacchetti S, Poz D, Giorda G et al (2007) Tamoxifen and its main metabolites serum and tissue concentrations in breast cancer women. Ther Drug Monit 29:349-352 (Pubitemid 47262266)